reference/33943813

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/33943813

Outgoing Links

Predicate	Object
contentType	Journal Article
issn	2072-6694
issueIdentifier	7
pageRange	1793-
publicationName	Cancers
startingPage	1793
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_4642769871a2060d09df5c7e96fd57cd http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_35bd4f80a7c1edf8020c308c4adbf881
bibliographicCitation	Garcia-Foncillas J, Bokemeyer C, Italiano A, Keating K, Paracha N, Fellous M, Marian M, Fillbrunn M, Gao W, Ayyagari R, Lassen U. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers. Cancers (Basel). 2022 Mar 30;14(7). PMID: 35406565; PMCID: PMC8997457.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a1d8050c53ffe1d7017e8b0b6bb300a9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa1e033fbab85223b6f58b50f43f200d http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-6071-7810 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf8b5c834d42b089a564eaf629ccbd73 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c23861a4a5425e5baea1e71659753a2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb530bad5ad88764ee0c10914aa739ce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f63c217fb8a53cf917bcb8db5e5b1e7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_428721148091c51711edcabea552de9a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_741ead787ce0812811ed86b4279d6c6f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0d2944321aae3bf3f2a02b9518908ab3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_283b31f01ebec89472cdcfd62176ec5c
date	2022-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC8997457 https://pubmed.ncbi.nlm.nih.gov/35406565 https://doi.org/10.3390/cancers14071793
isPartOf	https://portal.issn.org/resource/ISSN/2072-6694 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/37563
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46188928 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_2ef67088f58feaecfd117f6df16c5fdf http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25141092 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a859cb0544a77c8802d6e610b2abf648 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_42b79d112172fc5649bc6ffc314eda93 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607

Total number of triples: 36.